By Peter Lin/ On 19 Dec, 2025

Entering China via US PPA: Don't Let These 3 Details Ruin Your Patent Strategy

The US Provisional Patent Application is one of the most useful tools in an early-stage inventor’s toolkit. For a relatively modest fee, you can lock in a filing date in the US for 12 months while you refine your design, test the market, and raise funds.

But I work with many founders who treat the PPA as a standalone decision — not as the starting gun in a global IP race. And when they later try to use that PPA as a priority basis for a China Patent filing, three specific details come back to haunt them.

Detail 1: The 12-Month Deadline Is Absolute — and It Runs from the PPA Date, Not the Non-Provisional

This is the most common confusion I encounter.

A US PPA grants you a 12-month priority window. Within those 12 months, you must file your US non-provisional application and, if you intend to pursue international protection, your PCT application — both claiming priority to the PPA.

The mistake: some founders file their non-provisional at month 11, then assume they have another 12 months to file internationally. That’s wrong. The PCT 12-month filing window runs from the PPA date, not the non-provisional date.

So if your PPA was filed on January 1, your PCT application (to eventually enter China) must be filed by December 31 of the same year — regardless of when you filed the non-provisional.

Miss the PCT deadline, and you lose Paris Convention priority from your PPA for all international applications, including China. Your China strategy doesn’t collapse entirely — you can still file later — but you lose the protection of your original filing date, meaning anything published or filed in the intervening period becomes prior art against you.

Detail 2: A Weak PPA Creates Unsupported Claims in China

US provisional applications are famously flexible. You don’t need formal claims. Many are essentially a first draft of the specification, or even a rough description with drawings attached. That’s fine for US purposes — the non-provisional can add rigor later, and the US prosecution history handles the detail.

China works differently.

When you file a Chinese patent application (through PCT national phase entry) claiming priority to your US PPA, CNIPA evaluates whether your claims are fully supported by the disclosure in the priority document. If the feature you’re trying to protect in China was not described in sufficient detail in the original PPA, you may not be able to claim it under that priority date.

In practice, what this means is:

A vague PPA that describes a concept may not support specific product claims in China.
Features added in the non-provisional draft that weren’t in the PPA lose the priority benefit in China even if they’re entirely consistent with the original invention.
A claim that’s new in the PCT application — not in the PPA — has an effective China filing date equal to the PCT filing date, not the PPA date.

The fix: draft your PPA with the same rigor you’d apply to a non-provisional. This costs more upfront, but protects your priority chain all the way to China.

Detail 3: PCT Is Your Bridge — and It Has Its Own Timing Logic

The recommended route from US PPA to China Patent protection is:

US PPA → PCT application (within 12 months of PPA) → China national phase entry (within 30 months of PPA)

This route gives you the maximum timeline: potentially 30 months from your PPA date before you commit to Chinese prosecution costs. That’s a meaningful runway for a startup.

But many founders skip the PCT step and try to file directly in China under the Paris Convention within 12 months. This is technically valid, but it creates a practical problem: you need a full Chinese translation of your complete patent application within 12 months of the PPA date. If your PPA was thin, rushed, or in early-draft form, 12 months may not be enough time to develop it into a China-ready application.

The PCT bridge solves this. File a PCT application by month 12, finalize your China strategy over the next 18 months, and enter China’s national phase by month 30 with a complete, properly translated application.

For US founders using PPAs as IP strategy, this three-step sequence is almost always the right structure. Speak with a China Patent Attorney before your PPA’s 12-month anniversary — not after.

Why These Details Matter Specifically in China

China operates on a strict first-to-file system. There is no grace period for prior disclosures (unlike the US). Any publication, product launch, or competitor filing that occurs between your PPA date and your China filing date could be counted against you — unless your priority claim is valid and your disclosure is adequate.

Getting all three details right means your original idea date is your protected date in China. Getting even one wrong means your China protection window may be much narrower than you think.

Planning a US-to-China patent strategy from a provisional application?

Our China Patent team can review your PPA and design a portfolio strategy that protects your priority chain. Speak with a China Patent Attorney before your 12-month window closes.

Latest Posts

Follow Peter’s China IP Briefings

Peter Lin publishes practical China IP commentary in three formats. Pick the one that fits how you work.

Follow Peter Lin on LinkedIn

Daily commentary on China IP decisions, trademark risk, patent timing, and manufacturing supplier issues — written for foreign businesses, not legal specialists.

Follow on LinkedIn

Newsletter

Subscribe to the China IP Gateway Newsletter

Periodic briefings from Peter Lin on China IP developments, client case notes, and strategic decisions worth understanding before they become urgent.

Subscribe via Contact

YouTube

Watch 60-Second China IP Shorts

Short-format video briefings on China IP questions that come up repeatedly in client conversations. Built for busy founders and product teams.

Watch on YouTube

China IP Guides

By Peter Lin/ On 10 Dec, 2025

12 vs. 30 Months: Mastering the Critical Windows for China Patent Protection

Two numbers define your strategic window for China Patent protection: 12 months and 30 months. Get them confused, miss one of them, or misunderstand what they actually trigger — and you could lose rights that no amount of money can recover later. I've seen this happen. A founder assumes the 30-month PCT deadline applies to their situation, misses the 12-month Paris Convention window, and loses China priority. The patent can still be filed, but it now faces prior art that didn't exist when the clock started. Let me walk through both windows precisely. The 12-Month Window: Your Priority Clock Starts Here When you file your first patent application anywhere in the world — whether a US provisional, a UK complete application, or a Chinese utility model — a clock starts. Under the Paris Convention, you have 12 months from that first filing date to file in other member countries (including China) and claim priority back to that original date. What "claiming priority" means in practice: if you file in China within 12 months of your original filing, CNIPA will treat your application as if it was filed on the original date. Any competing applications or disclosures that appeared after your original filing date won't be counted as prior art against you. The 12-month deadline is absolute. There is no extension. If you miss it, you cannot claim Paris Convention priority for that filing. What happens at month 12 if you're going via PCT? Nothing special — as long as you file your PCT application before the 12-month Paris Convention deadline. Your PCT application, filed within 12 months of your original application, preserves your priority date and pushes your real China national phase decision out to month 30. This is the key insight: filing a PCT application within 12 months doesn't mean you're entering China at month 12. It means you're buying time until month 30 while protecting your priority date. The 30-Month Window: Your China Entry Deadline If you've gone the PCT route, month 30 from your original priority date is when you must enter the Chinese national phase. This means:Submitting your Chinese translation of the full application Paying China's official filing fees (calculated on claim count and page count) Formally committing to prosecution in ChinaMissing the 30-month deadline is also absolute for most countries. China does not provide a general grace period for late national phase entry. A missed deadline means you must re-file without priority — and everything that's been published in the intervening 30 months can be used against you. The Zone Between 12 and 30 Months: Use It Most inventors and even some IP teams treat this 18-month window as administrative dead time. That's a waste. Here's how to use months 12–30 productively: Refine your claim strategy. Use this time to assess the Chinese market, identify your most commercially valuable claims, and prepare for the slimming strategy I've written about separately. You have until month 30 to decide exactly what claims you need in China. Commission quality translation. A Chinese patent translation done in a rush at month 29 is a liability. A translation reviewed over two to three months, with technical input from your team and legal review from a China Patent Attorney, is an asset. Watch the competitive landscape. PCT applications are published at 18 months from priority. That means by month 18, your application is public. Use the window from month 18 to 30 to monitor what competitors are filing in China — this directly informs whether your claim strategy needs adjustment. Amend under PCT Article 19 or 34. You have specific windows to amend claims and request preliminary examination during the international phase. These amendments can be used strategically to strengthen your position before China national phase entry. A Timeline You Should Pin to Your WallMilestone Deadline Consequence of MissingFile PCT application Month 12 from original filing Lose Paris Convention priorityPCT application published Month 18 Application becomes publicInternational Search Report Typically months 16–22 Evaluate claim viabilityPCT Article 19 amendments Before 16 months from priority Window to amend claims internationallyChina national phase entry Month 30 from priority Lose right to enter (no recovery)One Exception Worth Knowing Design patents (外观设计) in China follow a different, shorter path. The Paris Convention priority window for designs is only 6 months, not 12. If you're protecting a product's appearance — packaging, industrial design, device form factor — that 6-month window applies and moves much faster.Planning your China patent timeline? Our China Patent team manages your PCT timeline from first filing through national phase entry. Or speak directly with a China Patent Attorney about your specific situation.

China IP Guides

By Peter Lin/ On 23 Mar, 2026

We Filed in China — Can We Still Protect the Invention in Hong Kong? A Practical Guide for PCT and China Patent Applicants

A client recently wrote to me with a question that felt very familiar:"We already filed into China through PCT. Do we still have any option to file in Hong Kong? I was told this might be done on the back of the Chinese patent, but I also saw something online about a 6-month deadline after publication. Does that apply to our case?"This is one of those questions that sounds simple at first, but in practice it often determines whether a Hong Kong patent strategy is still alive or already lost. The short answer is: yes, Hong Kong may still be available after a China filing. But the route is separate, the timing is separate, and applicants often watch the wrong deadline. Hong Kong has its own patent system. A Mainland China patent does not automatically extend to Hong Kong, and Hong Kong protection must be handled on its own terms. Hong Kong currently offers standard patents and short-term patents; standard patents can be obtained either by the original grant route, known as standard patent (O), or by the re-registration route, known as standard patent (R). For clients who already filed through PCT and entered the China national phase, the best Hong Kong route is usually standard patent (R) based on CNIPA. Hong Kong expressly allows a standard patent (R) to be based on a patent granted by the China National Intellectual Property Administration, and the Hong Kong process for standard patent (R) is built as a two-stage filing system: first a request to record on Form P4, then later a request for registration and grant on Form P5. That is what many clients mean when they say, "Can we do Hong Kong on the back of the Chinese patent?" In substance, the answer is often yes. But the more precise answer is this: you may be able to use the China route as the designated patent route for Hong Kong, provided the Hong Kong time limits have not already expired. Why Standard Patent (R) Is Usually the Best Route After China For a China-linked case, standard patent (R) is usually the most natural route because it fits the filing structure the applicant has already chosen. Hong Kong's patent framework makes the distinction very clear: a standard patent (R) is based on an earlier corresponding patent application filed with a designated patent office, and CNIPA is one of those designated offices. A standard patent (R) application is subject mainly to formality examination, while a standard patent (O) is a direct Hong Kong filing subject to both formality and substantive examination. That difference matters in practice. If the invention is already being prosecuted in China, standard patent (R) often gives the cleaner route into Hong Kong. It follows the China track instead of opening a separate substantive examination path in Hong Kong. By contrast, standard patent (O) is a direct Hong Kong route and is generally more suitable when the applicant wants an independent Hong Kong filing track or cannot use the re-registration route. Hong Kong's own materials say standard patent (O) can be filed directly in Hong Kong and is subject to substantive examination, while standard patent (R) depends on the grant of the corresponding patent by the designated office. So for a client who has already gone PCT → China national phase, my first instinct is usually not to ask, "Should we file a fresh Hong Kong case?" My first question is: "Is the standard patent (R) window still open?" The Mistake Many Applicants Make: They Focus on the Wrong Date This is where real matters often go wrong. Some applicants think the Hong Kong deadline runs from the PCT international publication date. Others think it runs from the date they filed the Chinese national phase documents. Others assume they can wait until the CNIPA patent is granted and then decide later. For a PCT-based standard patent (R) route through CNIPA, Hong Kong's rules are more specific. The first-stage filing in Hong Kong must be made within six months after the relevant CNIPA event showing that the international application has entered the national phase in China. The exact trigger depends on the language of the international publication. If the international application was published by WIPO in a language other than Chinese, Hong Kong looks to the publication by CNIPA in its Patent Gazette of the relevant bibliographical data showing national phase entry. If the international application was published in Chinese, Hong Kong looks to the official notification by CNIPA showing that the application has entered the national phase in China. This point is extremely important. It means that the key Hong Kong deadline is often not the original PCT publication date, and not simply the day you filed into China, but the specific CNIPA publication or notification event recognized by the Hong Kong rules. In other words, for many cases the real question is not "Did we enter China?" but "What is the exact CNIPA trigger date for the Hong Kong six-month clock?" The Two-Stage Hong Kong Process After a China Filing If the timing is still open, the Hong Kong standard patent (R) route usually works in two clear stages. Stage 1: Request to Record The first stage is the request to record, filed on Form P4. For a PCT-based case entering China, Hong Kong requires the applicant to file this request within six months after the relevant CNIPA publication or notification event. Once the filing is accepted and formalities are in order, Hong Kong publishes the request to record in the Hong Kong Intellectual Property Journal. This is the stage many foreign applicants do not realize exists. They assume Hong Kong only becomes relevant after the China patent is granted. But by that time, the first Hong Kong deadline may already be gone. Hong Kong's FAQ also highlights this first-stage deadline as one of the non-extendible time limits for standard patent (R) matters. Stage 2: Request for Registration and Grant The second stage is the request for registration and grant, filed on Form P5. Hong Kong requires this to be filed within six months after the later of:the publication of the request to record in Hong Kong; or the grant of the designated patent by the designated patent office. For a China-based route, that designated office is CNIPA.Again, this deadline matters. Hong Kong's FAQ lists the second-stage filing deadline as another non-extendible time limit. So even after the first-stage filing is safely on record, the matter still needs to be docketed carefully through the China grant stage and the later Hong Kong filing stage. What If the China Case Takes a Long Time? That is a practical issue, because Chinese prosecution can of course take time. Hong Kong addresses this by allowing the applicant, in certain circumstances, to maintain the standard patent (R) application if the applicant cannot yet proceed to the second stage. The Hong Kong PCT-route guidance explains that if the case cannot proceed to the second stage, the applicant may wish to maintain the application before the expiry of the fifth or any succeeding year from the relevant anniversary of the designated patent application filing date following publication of the request to record. So the real docket is often not just:China grant → Hong Kong grantIt is more often:PCT enters China → CNIPA trigger event → Hong Kong P4 → wait → maintain if necessary → CNIPA grant → Hong Kong P5That is the structure clients should understand from the beginning. What Protection Term Do You Get? A granted standard patent (R) in Hong Kong can last for a maximum of 20 years from the filing date of the designated patent application, subject to annual renewal. The first renewal fee is due on the fourth anniversary of the filing date of the designated patent application following the grant of the Hong Kong standard patent (R), and renewals then continue on each anniversary date until the maximum term expires. Hong Kong also has a short-term patent route with a maximum protection term of 8 years, but for most international applicants looking at a serious China-plus-Hong Kong patent strategy, the more relevant comparison is between standard patent (R) and standard patent (O). When Might Standard Patent (O) Still Matter? Although standard patent (R) is usually the first route to consider after a China filing, standard patent (O) can still become relevant in some cases. The most obvious example is when the applicant has missed the six-month timing for the first-stage standard patent (R) filing. Another is when the applicant wants a direct Hong Kong filing rather than relying on the China grant track. Hong Kong's original grant route can be filed directly in Hong Kong, and in general there is no time limit for filing a standard patent (O), although if priority from a first application is claimed, the Hong Kong filing should generally be made within 12 months of the first application. Hong Kong also requires substantive examination for standard patent (O), which makes it a different strategic route from standard patent (R). So the practical order of analysis is usually this:First, check whether standard patent (R) is still available. If it is, that is often the best route. If it is not, then ask whether standard patent (O) still makes commercial and procedural sense.The Three Questions I Would Check First for Any Real Client Matter When a client asks whether Hong Kong is still possible after a China filing, I usually want three dates or facts immediately. First: What language was the PCT application published in? That determines whether the Hong Kong six-month clock is tied to a CNIPA Patent Gazette publication or a CNIPA official notification. Second: What is the exact CNIPA publication or notification date showing entry into the China national phase? Without that, you cannot safely calculate the Hong Kong first-stage filing deadline. Third: Has the CNIPA patent already been granted? If yes, you then compare that grant date with the Hong Kong publication date of the request to record, because the later of those two dates governs the second-stage filing deadline. Those three points usually tell you very quickly whether the Hong Kong route is still open, and if so, what needs to happen next. Final Takeaway If you already filed a patent in China, or entered China through PCT national phase, Hong Kong may still be available — and in many cases the best route is standard patent (R) based on CNIPA. But Hong Kong is not an automatic extension of Mainland China. It is a separate patent system with a separate filing structure and strict deadlines. The most common mistake is waiting too long because everyone is looking at the China grant and not at the earlier Hong Kong six-month trigger tied to the China national phase entry event. So if a client asks, "We already filed in China — can we still protect the invention in Hong Kong?" the best answer is not just "yes" or "no." The real answer is:"Possibly yes — but we need to check the China route, identify the exact CNIPA trigger date, and make sure the Hong Kong standard patent (R) window is still open."Need help reviewing whether your Hong Kong filing window is still open? We help international applicants assess China filings, PCT national phase entries, and follow-on Hong Kong patent options, including deadline checks and filing strategy. Get in touch →Frequently Asked Questions Does a China patent automatically cover Hong Kong? No. Hong Kong has its own patent system. A Mainland China patent does not automatically extend to Hong Kong. Hong Kong protection must be applied for separately under the Hong Kong system. What is usually the best Hong Kong route after a PCT application enters China? Usually the first route to evaluate is standard patent (R) based on CNIPA, because Hong Kong recognizes CNIPA as a designated patent office for the re-registration route. When does the first Hong Kong 6-month deadline start? For a PCT case entering China, the clock runs from the relevant CNIPA publication or notification event showing national phase entry, and the exact trigger depends on whether the PCT publication was in Chinese or another language. Do I need to wait for the China patent to be granted before filing in Hong Kong? No. In the standard patent (R) route, the first Hong Kong step is the request to record; that usually needs to be filed much earlier, before the China grant stage is complete. What if the standard patent (R) timing has already been missed? Then it may still be worth evaluating whether a direct standard patent (O) filing in Hong Kong is available and commercially justified. That route is separate and subject to substantive examination.

China IP Guides

By Peter Lin/ On 23 Mar, 2026

China Patent vs Hong Kong Patent: What Is the Difference?

A client once asked me a question that sounds simple, but actually reveals a very common misunderstanding:"We already filed in China. Doesn't that already cover Hong Kong?"The answer is no — and that misunderstanding is exactly why this topic matters. Many international applicants treat "China" and "Hong Kong" as if they were one patent territory. From a patent filing perspective, they are not. If you want enforceable patent rights in Hong Kong, you need to assess Hong Kong separately. A Mainland China patent does not automatically give you patent protection in Hong Kong. Hong Kong's own Intellectual Property Department says this clearly: patent protection is territorial, and applying for a patent in the Mainland does not automatically give protection in Hong Kong. That is the starting point. But the real practical difference goes further than territory. China and Hong Kong differ in patent structure, filing routes, examination model, protection term, and follow-on strategy. If a client is manufacturing, selling, licensing, or enforcing rights across Greater China, those differences matter. 1. The First Difference Is Territorial Scope A China patent protects you in Mainland China. A Hong Kong patent protects you in Hong Kong. One does not automatically extend to the other. That is why applicants who care about the Hong Kong market, Hong Kong imports, Hong Kong licensing, or Hong Kong enforcement need to consider a separate Hong Kong filing strategy. This is often the most important practical point for overseas applicants. If your supply chain, distributor structure, or enforcement planning includes Hong Kong, then "we already filed in China" is not the end of the analysis. It is only the beginning. 2. China and Hong Kong Do Not Even Classify Patent Rights in the Same Way In Mainland China, CNIPA recognizes three types of patent applications: invention, utility model, and design. Hong Kong uses a different structure. Hong Kong has two types of patents overall: standard patent and short-term patent. But within standard patents, Hong Kong further distinguishes between the original grant route, called standard patent (O), and the re-registration route, called standard patent (R). That means the comparison is not simply "China patent vs Hong Kong patent" as if both systems were built the same way. They are not. China divides patent rights by invention / utility model / design, while Hong Kong divides them by standard / short-term, and within standard patents, by O route / R route. 3. The Filing Logic Is Different In China, you file directly into the Mainland patent system through CNIPA. In Hong Kong, the filing logic depends on which route you choose. A standard patent (O) is a direct Hong Kong filing. A standard patent (R) is built on a patent granted by one of Hong Kong's three designated patent offices: CNIPA, the EPO for patents designating the UK, or the UKIPO. The process is made in two stages: Form P4 for the request to record, and Form P5 for the request for registration and grant. A short-term patent in Hong Kong is again different. It is based on a search report from an accepted searching authority and is generally granted after formality examination. It is also subject to a stricter claim structure than a standard patent. So when a client says, "We want a Hong Kong patent," the real next question is not just "yes or no." The real question is: which Hong Kong route are we talking about? 4. The Protection Terms Are Different In Mainland China, the patent term is 20 years for inventions, 10 years for utility models, and 15 years for designs, all counted from the filing date. In Hong Kong, a standard patent has a maximum term of 20 years, while a short-term patent has a maximum term of 8 years, subject to the applicable renewal structure. This is one reason why clients should not assume that a "Hong Kong patent" is simply a mirror of their China filing. The term structure itself may differ depending on the route and the right chosen. 5. The Examination Model Is Also Different A standard patent (O) in Hong Kong goes through both formality and substantive examination. A standard patent (R) is based on a designated office patent and is subject only to formality examination in Hong Kong as to whether the required information and supporting documents have been properly filed. A short-term patent is generally granted after formality examination, but Hong Kong allows post-grant substantive examination upon request, and a short-term patent proprietor must request substantive examination before starting court proceedings to enforce the patent. That difference has real commercial consequences. In practice, it means the cost profile, timing profile, and enforcement planning can differ materially depending on which Hong Kong route is chosen. 6. If You Already Filed in China, Hong Kong May Still Be Available — But Not Automatically If the applicant already filed in China, that does not mean Hong Kong is automatically covered. But it may mean Hong Kong can be added through the standard patent (R) route, especially where the China filing sits within a larger PCT or designated-office structure. This is why, for many clients, the best Hong Kong strategy is not a fresh stand-alone filing but rather a careful review of whether the standard patent (R) route is available and whether the Hong Kong deadlines are still open. 7. The Hong Kong Deadlines Can Be the Real Trap For a Hong Kong standard patent (R), the filing is made in two stages. The first-stage request to record must be filed within six months after publication of the designated patent application in the designated patent office. The second-stage request for registration and grant must be filed within six months after the grant of the designated patent or the Hong Kong publication of the request to record, whichever is later. By contrast, Hong Kong's standard patent (O) and short-term patent routes are more flexible in one important respect: in general there is no time limit for filing, although priority claims usually require filing within 12 months from the first application. That practical distinction matters a great deal. It means that after a China filing, Hong Kong may still be possible — but the right route depends on where the matter sits procedurally and whether the standard patent (R) window has already been missed. 8. So Which System Should a Client Actually Think About? A client asking about China and Hong Kong usually needs a business answer, not just a doctrinal answer. If the commercial target is Mainland China only, then a China filing strategy may be enough. If the client also cares about Hong Kong transactions, Hong Kong imports, Hong Kong licensing, Hong Kong enforcement, or a Hong Kong-facing structure, then Hong Kong should be reviewed separately because the China filing does not automatically cover that territory. If the client already filed in China and wants to extend protection into Hong Kong, the first route to assess is often standard patent (R) based on CNIPA. If that timing is no longer workable, then the applicant may need to evaluate whether standard patent (O) or, in limited situations, a short-term patent makes more commercial sense. Final Takeaway A China patent and a Hong Kong patent are not the same right, and they do not arise from the same system. China uses a three-track patent structure of invention, utility model, and design. Hong Kong uses standard patents and short-term patents, and standard patents themselves split into the original grant route and the re-registration route. A China filing does not automatically protect Hong Kong. And if Hong Kong is commercially relevant, it should be assessed as a separate patent jurisdiction with its own routes, deadlines, and strategic choices. So when a client asks, "What is the difference between a China patent and a Hong Kong patent?" the most practical answer is this:A China patent protects Mainland China. A Hong Kong patent protects Hong Kong. The legal structures, filing routes, and deadline risks are different — and that difference can directly affect whether protection is still available.Need help reviewing whether a China filing should be extended into Hong Kong? We help international applicants assess China patent filings, Hong Kong patent options, and follow-on route strategy based on the actual procedural posture of the case. Get in touch →Frequently Asked Questions Does a China patent automatically cover Hong Kong? No. Hong Kong patent protection is territorial, and a Mainland China patent does not automatically extend to Hong Kong. What types of patents exist in China? China recognizes invention, utility model, and design patents. What types of patents exist in Hong Kong? Hong Kong has standard patents and short-term patents. Standard patents can be obtained through standard patent (O) or standard patent (R). What is usually the best Hong Kong route after a China filing? Often the first route to evaluate is standard patent (R) based on CNIPA. What if the Hong Kong standard patent (R) deadline has been missed? Then it may still be worth evaluating whether a direct standard patent (O) filing, or in some cases a short-term patent, is still commercially appropriate.

China IP Guides

By Peter Lin/ On 19 Mar, 2026

Before You Manufacture in China: How Trademark, Patent, and Contract Protection Work Together

Many foreign startups and product companies treat China entry as if it were a sequence of separate legal tasks. First, they think about patents. Later, they think about trademarks. Then, once a factory conversation gets serious, they suddenly think about NDAs, NNN agreements, OEM terms, molds, or production control. That structure feels logical on paper. But in real China-facing work, it often breaks down because those risks do not arise one by one. They overlap. The Real Problem The real problem is not that foreign companies ignore protection completely. It is that they handle protection in the wrong order. A startup may delay trademark thinking because it is “still in sourcing mode.” A product team may delay patent action because it is “still refining the product.” A founder may delay contract structure because the supplier “seems friendly.” By the time those issues are revisited, the business may already have:shared product drawings; circulated the brand name in supplier networks; started tooling discussions; exposed its go-to-market plan; created a record of movement without a coordinated protection structure.Why These Three Layers Should Be Planned Together The reason trademark, patent, and contract protection work together is simple: They protect different kinds of value at different stages of the same commercial move. Trademark protects brand-side value Your name, logo, and China-facing brand identity need to be considered before they spread through packaging, sourcing, distribution, or launch activity. Patent protects product-side value Your product structure, technical features, and protectable design logic may need to be filed before deeper disclosure or manufacturing-stage exposure makes delay more dangerous. Contract protection controls factory-side behavior Your supplier agreement structure helps define what can and cannot be done with your information, tooling, processes, contacts, and production knowledge. When these are treated as isolated tasks, the company loses sequencing discipline. When they are planned together, the protection logic becomes much stronger. A Practical Example Imagine a hardware startup with a new consumer device. It wants to do five things quickly:speak to a Chinese factory; show a CAD file; discuss tooling; confirm packaging options; begin branding conversations.At first glance, this looks like a sourcing and product development issue. But it is also:a patent timing issue; a trademark visibility issue; a supplier-side contract issue.If the team files nothing, signs nothing useful, and circulates the brand widely, the first irreversible move may come from the business side before the legal side ever catches up. What Usually Matters First The best first move depends on what is about to be exposed first. If the brand is moving first Start with a practical China Trademark review. This is especially true if suppliers, packaging vendors, or early commercial partners are already seeing the mark. If the product itself is moving first Look at China Patent Filing Support before disclosure deepens. If the value lies in structure, mechanism, or protectable design, waiting can narrow your options. If supplier conversations are moving first Review China NNN & OEM Agreements. A supplier-stage relationship can create misuse and bypass risk even before manufacturing formally begins. If all three are moving at once That is more common than many teams realize. In that case, you do not need three disconnected answers. You need a sequenced plan. What Foreign Teams Often Misjudge Foreign teams often make one of these four mistakes. Mistake 1: “We will handle the trademark after launch planning” But brand visibility can start long before launch. Mistake 2: “We can patent later if the product does well” By then, the key timing window may no longer look the same. Mistake 3: “An NDA is enough for now” Often it is not, especially if the real issue is supplier-side use, workarounds, or commercial bypass. Mistake 4: “These are separate workstreams” In reality, China entry problems often become expensive because the workstreams were separated too long. A Better Way to Sequence the Work A practical China entry sequence often looks like this: Step 1: Clarify what value matters most Is the immediate exposure in the brand, the product, the factory conversation, or all three? Step 2: Lock the first vulnerable layer Do not protect what feels most abstract. Protect what is about to become exposed. Step 3: Add the second layer before scale-up Once supplier engagement grows, your next layer should not wait too long behind. Step 4: Build the manufacturing-stage structure By the time tooling, pricing, and production terms are being discussed, contract architecture should no longer be optional. Where the Services Connect This is exactly why China IP Gateway now has different service paths that still connect:China Trademark for brand-side protection and naming strategy; China Patent Filing Support for route, timing, and filing support; China Patent Attorney for more strategy-led patent work; China NNN & OEM Agreements for supplier-side and manufacturing-stage control.This is not a menu of isolated legal products. It is a way of helping foreign companies protect the right layer at the right stage. When You Need a Practical First Review A practical first review is especially useful if you are in one of these situations:you are about to disclose product information to a Chinese factory; your brand name is already being shown in supplier or packaging discussions; you are choosing between invention patent, utility model, or waiting; you have an NDA but are unsure whether it is enough; you do not know which issue should move first.At that stage, the goal is not to file or sign everything immediately. The goal is to avoid making your first irreversible move without a protection sequence. Frequently Asked Questions Do I always need all three layers? Not always in the same depth. But many foreign product companies need at least some coordinated thinking across all three earlier than they expect. What if I am only testing suppliers? Testing suppliers is often exactly when risk begins. Early-stage sourcing does not automatically mean low exposure. Is this only relevant for large companies? No. In fact, smaller teams often benefit even more from sequencing correctly because they have less room for expensive correction later. Final Thought China manufacturing risk is rarely caused by one dramatic mistake. More often, it comes from a series of “we’ll handle that later” decisions that let exposure outrun structure. Before you manufacture in China, the smartest move is usually not just to ask for one document or one filing. It is to ask how your trademark, patent, and contract protection should work together before the business moves faster than the protection around it. If you are already at that point, start with Services Overview, Pricing, or Talk to Us.

China IP Guides

By Peter Lin/ On 05 Dec, 2025

From Idea to Income: Navigating the Chinese PCT National Phase with the Slimming Strategy

When an inventor files a PCT application, the instinct is always to go broad — claim everything you can while the window is open. That instinct is not wrong. But there's a moment, usually around month 28 or 29, when you have to make a very practical decision about China. Do you enter the Chinese national phase with your full PCT claim set — or do you slim it down first? This is a question I've helped hundreds of foreign founders and IP teams navigate. And the right answer almost always involves what I call the slimming strategy. Why China's National Phase Is Different China's China Patent system is built on a "first to file" principle, and CNIPA processes a staggering volume of applications — nearly half of all PCT national phase entries globally. That volume means the system has developed detailed, and sometimes strict, fee structures. Here's the key cost driver most applicants miss: China charges extra official fees for each claim beyond the tenth. If your PCT application entered with 25 claims, you're paying surcharges on 15 of them — before you've even had a single substantive examination. That's not the only cost lever. You're also paying for translation of your entire application into Chinese, typically at a per-character or per-word rate. A long, broad specification with dozens of unnecessary claims multiplies at every step. What the Slimming Strategy Actually Means The slimming strategy is not about giving up protection. It's about entering China with a claim set tailored to what the Chinese market actually needs to protect. Here are the three steps I walk clients through: 1. Audit your claims for China relevance. A US or EU patent may have claims covering specific regulatory contexts, component configurations, or use cases that don't exist in the Chinese market. Strip those before national phase entry. They add cost without adding value. 2. Reduce claim count to 10 or below where possible. If you can consolidate dependent claims without losing core protection, do it before filing the Chinese translation. Every claim above 10 triggers an additional fee at CNIPA. 3. Sharpen your independent claims for the Chinese enforcement context. In China, the enforceability of a patent often comes down to one or two independent claims. Make them tight, clear, and commercially relevant. Abstract claims that might survive in Europe often fail or become unenforceable in Chinese courts. The Right Time to Slim This is critical: you must make slimming amendments before or at the time of national phase entry, typically by the 30-month deadline from your priority date. Amending claims after entering national phase is possible but triggers additional examination rounds and costs. Under PCT Article 19, you can amend claims at the international phase before entering China. Use that window. Work with a China Patent Attorney who understands both Chinese patent law and the commercial context of your product. What Founders Often Get Wrong I see two common mistakes: Mistake 1: Entering with the full PCT claim set to "keep options open." This is expensive and tactically weak. You're paying to protect claims you'll likely never enforce, and bloating your specification makes Chinese examination slower and more contentious. Mistake 2: Slimming too aggressively. Some applicants, trying to cut costs, drop claims they'll later need — especially around manufacturing methods or component-level protection. If copycats are your main risk in China, you often need both product and method claims. The balance point depends on your industry, your enforcement likelihood, and your budget horizon. From Idea to Income: Why Claim Quality Beats Claim Quantity The title of this article uses the word "income" deliberately. A Chinese patent that exists on paper but is never enforced, never licensed, and never cited in a deal is not generating income — it's generating filing fees. Practically, a well-slimmed Chinese patent has immediate commercial value in three situations: Licensing negotiations. When a Chinese manufacturer or distributor is assessing whether to take a license, they want clean, narrow claims — not a sprawling set that a good lawyer can pick apart. A 10-claim application with two irrefutable independent claims is worth more in a licensing meeting than a 30-claim application that invites dispute. Investment due diligence. Foreign investors and acquirers looking at your China market position will assess your registered IP. Clear claim scope with a clean prosecution history signals that the patent was filed with enforcement in mind. Distributing exclusivity. If you want to appoint an exclusive distributor in China, a slimmed, granted patent with specific product claims gives that distributor something real to enforce against copycats. If you're approaching your 30-month deadline and haven't yet thought through your China entry strategy, that conversation needs to happen now — not after CNIPA acknowledges your filing.Need help choosing the right China patent entry strategy? Explore our China Patent services or speak with a China Patent Attorney to plan your national phase entry the right way.

China IP Guides

By Peter Lin/ On 23 Mar, 2026

Missed the Hong Kong Re-Registration Window: Can Standard Patent (O) Still Help?

A client once came to me with a frustrating but very realistic question:"We already filed through PCT and entered China. We later learned that Hong Kong had a separate filing route, but by the time we checked, the Hong Kong re-registration deadline may already have passed. Is there still anything we can do?"This is exactly the kind of situation that causes unnecessary loss of rights. Many applicants only discover Hong Kong late in the process. They assume that a China patent filing somehow covers Hong Kong, or they assume Hong Kong can simply be added later once the China case moves forward. But Hong Kong has a separate patent system, and one of its most important routes — standard patent (R) — comes with strict filing windows. A standard patent (R) application is made in two stages, and the first-stage request to record must be filed within six months of the relevant designated-office publication event; the second-stage request for registration and grant must then be filed within six months after grant of the designated patent or publication of the request to record in Hong Kong, whichever is later. Hong Kong's own guidance highlights these as non-extendible time limits. So what happens if that window has already been missed? The answer is not a simple yes or no. In some cases, standard patent (O) may still be worth evaluating. In other cases, it may already be too late in practical terms because the invention has been publicly disclosed, the priority period has expired, or the commercial value no longer justifies a fresh Hong Kong filing. Hong Kong expressly allows a standard patent (O) to be filed directly in Hong Kong and subjects it to both formality and substantive examination. But that does not mean it can always rescue a missed standard patent (R) case. 1. First, What Exactly Has Been Missed? Before asking whether standard patent (O) can help, it is important to be precise about what deadline was missed. Hong Kong's standard patent (R) route is based on a patent granted by one of three designated patent offices: CNIPA, the EPO for patents designating the UK, or the UKIPO. It is a two-stage process: Form P4 for the request to record, and Form P5 for the request for registration and grant. The first-stage filing must be made within six months after publication of the corresponding designated patent application, and the second-stage filing must be made within six months after grant of the designated patent or publication of the request to record in Hong Kong, whichever is later. Both are treated by Hong Kong as non-extendible. In practice, that means the phrase "we missed the Hong Kong window" usually refers to one of two things:the applicant missed the first-stage P4 filing for standard patent (R); or the applicant got through stage one but missed the second-stage P5 filing after grant.If either of those has happened, the applicant generally cannot simply revive the standard patent (R) route by asking for more time. That is why attention then turns to whether a standard patent (O) filing is still viable. 2. Why Standard Patent (O) Becomes Relevant Hong Kong's standard patent (O) is different from standard patent (R). It does not require an earlier corresponding application in one of the designated patent offices as a filing precondition. Hong Kong says directly that a standard patent (O) application can be filed directly in Hong Kong, without filing an earlier corresponding patent application elsewhere in support. It is then examined for both formality and substantive compliance, including whether the invention is new, involves an inventive step, and is industrially applicable. This is why standard patent (O) is the first backup route people think of after missing standard patent (R). If the re-registration door is closed, the direct-filing door may still be open. But "may" is the critical word. A standard patent (O) filing is not a reset button. It is a separate patent application that still has to survive patentability review. And Hong Kong's own FAQ warns very clearly that novelty will generally be lost upon disclosure, including publication of a patent application. Hong Kong even notes that where an invention has already been published in a patent application that is later abandoned, withdrawn, or refused, re-filing may face novelty objections or challenges. 3. The Key Question: Has Novelty Already Been Destroyed? This is the real turning point. Hong Kong's novelty guidelines state that the state of the art covers everything disclosed in Hong Kong or elsewhere in the world, including disclosure by written or oral description or by use. That is a broad rule. So if the invention has already been made public — for example through PCT publication or another published patent application — that disclosure may become prior art against a later Hong Kong standard patent (O) filing unless a valid priority claim or another narrow exception applies. This is why standard patent (O) is often still useful only if one of the following is true:the Hong Kong standard patent (O) filing is still being made within the priority window from the first filing; the applicant can still restore the priority right within Hong Kong's limited restoration mechanism; or the relevant disclosure falls into Hong Kong's narrow non-prejudicial disclosure exception.Without one of those, a later standard patent (O) application may be technically fileable, but substantively weak or even doomed. Hong Kong itself says that, in general, there is no time limit for filing a standard patent (O) application, but also emphasizes that novelty is generally lost upon disclosure. That combination is exactly why applicants sometimes misunderstand the system: they hear "no time limit" and assume "no urgency," when the real urgency comes from novelty and priority, not just filing mechanics. 4. When Standard Patent (O) Is Most Likely to Help In practice, standard patent (O) is most likely to help where the applicant missed the standard patent (R) route but is still within a legally meaningful timing position for a direct Hong Kong filing. Scenario A: Still within 12 months of the first filing Hong Kong says that, in general, there is no time limit for filing a standard patent (O) application, but if the applicant wants to claim priority from a first application in a Paris Convention country or WTO member, the Hong Kong filing should be made within 12 months of that first filing. This is the cleanest rescue scenario. The applicant may have lost the re-registration path, but a direct Hong Kong standard patent (O) filing with a proper priority claim may still be available. Scenario B: Just outside 12 months, but still within restoration window Hong Kong also allows an application for restoration of priority right in some cases. If the applicant failed to file the standard patent (O) application within the normal 12-month priority period, Hong Kong says the applicant can still file and seek restoration of priority right provided that the restoration request is made within 14 months from the date of filing of the previous application and before publication preparations for the Hong Kong application are completed. Hong Kong further requires evidence, in the form of a statutory declaration, showing why the filing was late and satisfying the Registrar that all reasonable care required by the circumstances had been taken. This is an important but narrow safety valve. It is not automatic, and it is not available indefinitely. Scenario C: Very limited pre-filing disclosure exception Hong Kong also recognizes a narrow non-prejudicial disclosure exception. A disclosure will not count against the invention only if it occurred within 6 months before filing and resulted from either evident abuse such as breach of confidence, or display at an officially recognized international exhibition. Hong Kong requires a disclosure statement and supporting evidence for this claim. This is useful in a small number of cases, but it should not be confused with a general grace period for ordinary business disclosure or routine patent publication. 5. When Standard Patent (O) May No Longer Be a Realistic Rescue There are also many cases where standard patent (O) may no longer be the right answer. If the invention has already been publicly disclosed and the applicant is outside the 12-month priority period, outside the 14-month restoration window, and outside the narrow 6-month non-prejudicial disclosure situation, a new Hong Kong standard patent (O) filing may face serious novelty problems. Hong Kong's own FAQ is quite blunt that novelty would generally be lost upon disclosure, including publication of a patent application. That does not mean filing is literally impossible in every such case. But it does mean the applicant should not assume that standard patent (O) can reliably "repair" the missed re-registration route. Sometimes the better answer is commercial rather than legal: accept that the Hong Kong patent window has narrowed or closed, and decide whether other forms of protection or business structuring matter more. 6. Standard Patent (O) Also Comes With Its Own Prosecution Burden Another reason standard patent (O) is not a simple substitute is that it requires real prosecution in Hong Kong. Hong Kong requires the applicant to file a request for substantive examination of a standard patent (O) application within three years after the filing date or earliest priority date claimed, failing which the application will be regarded as withdrawn. During substantive examination, the Registrar assesses whether the application meets the examination requirements, including patentability of the invention. So even where standard patent (O) is still available, it is a different kind of project from standard patent (R). Standard patent (R) largely rides on the designated patent track; standard patent (O) requires a direct Hong Kong prosecution path. 7. A Practical Way to Analyze the Situation When a client asks whether standard patent (O) can still help after a missed re-registration window, I usually work through the following questions in order. First, which Hong Kong deadline was missed — the first-stage request to record, or the second-stage request for registration and grant? Hong Kong treats both as non-extendible in the standard patent (R) route. Second, what is the earliest filing date we can still rely on for priority? If the first filing was less than 12 months ago, the standard patent (O) route may still be relatively clean. If it is between 12 and 14 months, restoration of priority may still need to be evaluated urgently. Third, what disclosures have already happened? Hong Kong's novelty rule is broad, and public disclosure can be fatal unless priority or a narrow exception protects the case. Fourth, does Hong Kong still matter commercially? Even if standard patent (O) is still technically possible, it should still make business sense in light of cost, timing, and actual Hong Kong relevance. Final Takeaway Missing the Hong Kong standard patent (R) deadline does not always end the story. In some cases, standard patent (O) can still help — especially where the applicant is still within the normal 12-month priority window, or possibly within Hong Kong's limited 14-month restoration mechanism. Hong Kong also permits a narrow 6-month non-prejudicial disclosure exception for abuse or qualifying exhibition disclosures. But standard patent (O) is not a universal rescue tool. If the invention has already been publicly disclosed and the relevant priority or exception structure is gone, a late direct Hong Kong filing may offer little real value. Hong Kong's own materials make the core risk clear: novelty is generally lost upon disclosure, and a standard patent (O) application must still survive substantive examination. So if the question is: "We missed the Hong Kong re-registration window. Can standard patent (O) still help?" the honest answer is:"Sometimes yes — but only if the timing, disclosure history, and priority position still support a viable direct Hong Kong filing."Need help checking whether Hong Kong standard patent (O) is still worth pursuing after a missed re-registration deadline? We help international applicants review timing, priority, publication history, and route selection for China and Hong Kong patent strategy. Get in touch →Frequently Asked Questions If I miss the Hong Kong standard patent (R) deadline, can I simply ask for more time? Usually no. Hong Kong identifies the key first-stage and second-stage filing periods for standard patent (R) as non-extendible. Can standard patent (O) be filed directly in Hong Kong? Yes. Hong Kong says a standard patent (O) application can be filed directly in Hong Kong without needing an earlier corresponding application in one of the designated patent offices. Does Hong Kong standard patent (O) have a filing deadline? In general, Hong Kong says there is no time limit for filing a standard patent (O) application. But that does not remove novelty or priority risks. If priority is to be claimed, the filing should normally be made within 12 months of the first application. Can I restore priority if I miss the normal 12-month priority period? Possibly. Hong Kong allows an application for restoration of priority right if it is made within 14 months from the filing date of the previous application and before publication preparations are completed, with evidence showing that all reasonable care had been taken. What is the biggest risk in relying on standard patent (O) as a rescue route? Novelty. Hong Kong states that novelty is generally lost upon disclosure, including publication of a patent application, unless a valid priority claim or a narrow non-prejudicial disclosure exception applies.

China IP Guides

By Peter Lin/ On 20 Mar, 2026

PCT Translation Errors in China: What Foreign Applicants Can Correct, and When

Most foreign applicants submit a PCT translation into Chinese and move on. The translation is outsourced, filed under deadline pressure, and rarely reviewed against the original international application text. In many cases it is fine. But in a meaningful number of cases it is not — and when a translation error in China patent prosecution affects claim scope, the consequences can be permanent. This guide explains what correction is actually available, when it must happen, what makes a change qualify as a genuine translation correction versus an amendment, and how the situation differs depending on how you filed in China in the first place. Why This Issue Matters More Than Most Foreign Applicants Expect Translation in patent work is not a purely linguistic task. It makes legal commitments. A Chinese translation of a PCT application becomes the operative text for prosecution in China — and eventually for enforcement. If the translation unduly narrowed a claim because a technical term was rendered too specifically, or if a feature was added that was not in the original, the Chinese patent that results will not accurately reflect what the applicant actually invented. The commercial stakes are real. An overly narrow claim in China may fail to catch a competitor whose product would clearly have fallen within the scope of the original English claims. A translation that introduced a feature not in the original could expose the patent to an invalidity challenge after grant. Neither outcome is easy to manage, and neither is cheap to fix if it is fixable at all. What foreign applicants often miss is that unlike some jurisdictions where post-grant correction is relatively accessible, China's system is comparatively unforgiving once a patent is granted. The windows to act exist — but they close, and they do not reopen. First, Separate Two Very Different Situations: PCT Entry vs Paris Filing The most important distinction to establish before anything else is this: how did you file in China? If you filed an international application under the PCT and later entered China national phase using a Chinese translation of that international application, you are in a different legal situation from someone who filed a Paris Convention direct application in Chinese from the start. For PCT national phase entries, Chinese law recognises that the Chinese translation is not the original — the international application filed with the receiving office is. This creates space for a translation correction mechanism, because there is a defined reference text against which the Chinese translation can be checked. The rules governing PCT entry into China — filing timelines, language requirements, and the translation submission process — are described in more detail in the guide on 12 vs. 30 months and the critical windows for China patent protection. For Paris Convention direct filings in Chinese, the Chinese text you filed is the original. There is no foreign-language source to correct against. General amendment rules apply, and translation correction as a concept does not exist. These two routes operate under different rules and require different approaches to error management. Conflating them is one of the more consequential mistakes in managing a China patent portfolio. What China Usually Allows for PCT Translation Corrections China's Patent Law Implementing Regulations provide that where an international application was filed in a foreign language and the Chinese translation deviates from the original international application, the applicant may request that CNIPA amend the Chinese text to conform to the original. The governing standard in practice: the correction must be based on the text of the original international application as filed at the PCT receiving office — the International Bureau's record of the application as it existed on the international filing date. Later amendments made during the international phase, whether through Article 19 (claims amendments) or Article 34 (examination amendments), are not automatically the baseline unless those amended texts were formally designated for entry into China. The purpose of this mechanism is narrow. It is designed to restore accuracy — to bring the Chinese text into alignment with what the original actually said. It is not a vehicle for improving claim coverage, responding to prior art identified during prosecution, or adding technical content that was not in the original disclosure. The Two Time Windows That Matter In practice, there are two main moments when a translation correction in China is realistically pursued. Window one: voluntary correction before CNIPA raises a concern. A translation correction request can be filed at any point before the patent is granted. In practice, the earlier the better — ideally before or at the start of substantive examination, before the examiner has relied on the translated text to form any view on the claims or the disclosure. Some applicants with significant China patent programs now conduct a brief translation review of claim language shortly after national phase entry, specifically to catch material errors at this early stage. The cost of doing so is a fraction of the cost of managing the consequences later. Window two: in response to an Office Action. CNIPA examiners do occasionally identify apparent inconsistencies between the Chinese claim language and what the description suggests the invention actually is. Where the underlying reason is a translation error, this is often the first moment a foreign applicant becomes aware of the problem. The response period to the Office Action then becomes the operative correction window. Missing it, or filing a response that does not properly address the translation issue, can produce a permanent narrowing. What there is not, in most cases, is a meaningful correction window after the patent has been granted. Post-grant correction in China is procedurally difficult and not generally available as a practical remedy for scope problems that trace to translation errors. What Usually Counts as a Real Translation Error Not every disappointing outcome in a Chinese patent claim reflects a translation error. The concept has a defined meaning. Translation errors that typically qualify for correction include: Linguistic divergence from the original — where a technical term was rendered using a Chinese expression that carries a different scope or meaning from the original, and the correct translation is objectively clear when the two texts are read side by side. Structural inversions — where a sentence in the original describes a limitation as optional but the Chinese translation rendered it as mandatory, or vice versa, in a way that clearly misrepresents the original syntax. Omissions — where a phrase or clause clearly present in the original was dropped from the Chinese translation, and the omission is visible without any interpretive judgment. The unifying principle is objective: the Chinese text should have said something specific, it did not because of a translation failure, and the original supports the proposed correction without needing to read anything into it. What Usually Does Not Qualify The limits of translation correction are regularly tested, usually by applicants who want to recover claim scope for reasons that are not about translation fidelity. Adding a technical feature not present in the original international application does not qualify, even if the inventor believes it would strengthen the claims or better describe the actual product. This is new matter, not linguistic restoration. Expanding claim scope in a direction the original text does not straightforwardly support similarly falls outside the mechanism. CNIPA will assess whether the proposed correction reflects what the original actually said. If the correction requires reading the original in a way that is not objectively supported by its text, it will be treated as an amendment rather than a correction — and assessed under more restrictive rules. Using "translation correction" to clean up informal or imprecise expression in the original description is also not available. The mechanism corrects the Chinese rendering of a text; it does not improve the underlying text itself. The practical test is reasonably direct: would a competent translator, working carefully from the original, have produced the corrected Chinese text? If the answer requires a fresh technical or legal judgment rather than a straightforward linguistic reversal, the proposed change is unlikely to be accepted as a mere translation correction. Translation Correction vs Ordinary Amendment These are two distinct mechanisms, and the distinction has substantive consequences. A translation correction, when accepted, is treated as restoring what the original text actually said. The corrected Chinese text is read as having been the correct translation from the outset — it changes the operative text of the application back to what it should have been. An ordinary amendment under China Patent Law is subject to a different and more limiting standard: it cannot introduce content that goes beyond the scope of what was disclosed in the original application. Crucially, for PCT cases, the baseline for amendment purposes is the Chinese translation as originally submitted — not the original foreign-language international application. If your Chinese translation is narrower than the original, you generally cannot use an ordinary amendment to recover the broader scope, because the narrower Chinese translation is what CNIPA treats as defining the disclosure for amendment purposes. This asymmetry is what makes the translation correction mechanism so important: if a material narrowing error is not caught and corrected within the translation correction framework, ordinary amendment may not be sufficient to fix it at all. The scope is simply gone. For a related discussion of how amendment rules work in PCT cases more broadly, the guide on how much you can amend claims when entering China via PCT covers the "no new matter" rules and common mistakes in detail. What About Paris Convention Direct Filings? For a Paris Convention direct filing in Chinese, the Chinese text filed is the original application. There is no foreign-language reference document from which a translation correction can be requested. The general amendment rules under China Patent Law apply. Voluntary amendments can be made within a defined early window after filing. Amendments in response to Office Actions are permitted within the prescribed response periods. In both cases, the governing constraint is the same: amendments cannot introduce technical content beyond the scope of the original disclosure. Since the Chinese text is the original, the question of what "the original said" and what the translation "should have said" simply does not arise. In practice, Paris Convention direct filings into China are typically prepared in Chinese from the start by a China-registered patent attorney, and the national-phase translation problem does not apply in the same form. The risks are of a different character — incomplete disclosure, claim language that does not match the description, terminology inconsistencies — and they are addressed through the general amendment process rather than any translation-specific mechanism. What Happens If You Do Nothing? If a translation error is identified but not acted on, the consequences depend on the nature of the error and where the application is in its lifecycle. An error that narrowed the claims and was never corrected may result in a patent that grants with claims too narrow to be useful — and with no mechanism to recover the original scope after grant. The commercial asset the applicant expected to hold in China may be materially weaker than anticipated. An error that introduced content not in the original, if identified by CNIPA during examination, will produce an objection that the claims or description lack support in the original. If the error is identified only after grant, by a third party seeking to challenge the patent, it can form the basis of a well-founded invalidation action. An error that distorts the meaning of a technical feature creates prosecution history risks: CNIPA's examination record reflects the Chinese text, including the error, and this record is relevant to later infringement analysis. A patentee relying on a Chinese claim that diverges from the original may face difficult questions about scope and intent. The real risk of inaction is not always visible during prosecution. Applications often grant without the translation error being raised. The consequences surface when the patent is needed — in enforcement, licensing, or a dispute — and by then the correction window is long closed. A Simple Internal Review Method for Foreign Applicants Foreign applicants managing a China patent portfolio with PCT entries can reduce translation-related risk with a straightforward internal review practice. After receiving confirmation of national phase entry and the Chinese filing documents, request a reverse translation of the claims: a translation from the Chinese claims back into English, done by someone who has not seen the original English claims. Then compare this reverse translation against the original international application claims side by side. Differences in scope, omitted elements, and structural inversions typically become visible in this exercise without requiring deep technical expertise. The review is not looking for every nuance — it is looking for material divergences that could affect what the patent actually covers. Where a material divergence is identified, consult with a China patent attorney on whether the issue qualifies for a translation correction, an ordinary amendment, or requires a different strategy. The earlier this consultation happens after national phase entry, the more options are available. This practice is not a substitute for a full professional review of the description and drawings — but for claim scope, which is where translation errors most often cause commercial harm, it is a practical and low-cost step that a significant number of applicants currently skip. For those still evaluating whether and when to enter China via PCT — including the timing decisions that affect which correction tools are even available — the PCT national phase slimming strategy guide covers the strategic framework for that earlier decision. Final Takeaway Translation errors in China patent applications are not rare, and they are not always visible during prosecution. For PCT national phase entries, Chinese law offers a correction mechanism — but it is bounded. It requires a genuine translation error. It requires the proposed correction to be grounded in the original international application text. And it has time windows that close before grant and do not reopen. What foreign applicants need most is not a comprehensive map of every procedural rule, but a practical habit: review the Chinese translation of your claims after national phase entry, before substantive examination begins. If something looks materially wrong against the original, act early. The cost of a translation correction request at that stage is a fraction of what it costs to manage a scope problem after grant — or to lose the scope entirely. If you are working through a China patent filing and have questions about translation review, national phase entry strategy, or claim scope, the China Patent Filing and China Patent Attorney pages describe how we work with foreign applicants on these questions directly.

China IP Guides

By Peter Lin/ On 03 Dec, 2025

Provisional vs. Non-Provisional Patent Applications — Which One Fits Your Kickstarter Launch?

I’m Peter Lin — over the past decade, I’ve helped creators and companies file more than 200 U.S. patent applications. One question I hear again and again — especially from Kickstarter founders — is: “Should I start with a provisional or a non-provisional patent application?” It’s a simple question with a strategic answer. Let’s break it down — from one innovator to another. ⚙️ 1. What’s the Real Difference? Provisional Application Think of it as a 12-month placeholder for your idea. You don’t need formal claims or declarations — just a clear written description and drawings. Once filed, you can label your product as “Patent Pending.” Non-Provisional Application This is the formal patent application that gets examined by the USPTO. It must include claims, drawings, and a declaration. Only after this step can your patent be granted and enforceable. 🧭 2. Which Should You Choose? Your Situation Better Option Why Still refining your prototype Provisional Cheaper, faster, buys you 12 months to improve or test market fit. Ready for full protection Non-Provisional Starts examination immediately; no need to re-file. Tight budget, early Kickstarter stage Provisional Gives you “patent pending” status to attract backers and investors. Confident in technical maturity Non-Provisional Saves time — goes straight to real examination. 💡 3. My Experience-Based Advice After reviewing hundreds of U.S. filings, here’s what I tell early inventors: File something before you go public. Even a rough draft of your invention can lock in your priority date. Use the provisional year wisely. Improve your prototype, talk to investors, validate demand — but remember to convert it into a non-provisional before the 12-month deadline. Don’t treat the provisional as “half-work.” It still needs enough technical detail to prove you actually possessed the invention. For Kickstarter projects: A provisional often makes perfect sense. It gives you credibility (“Patent Pending”) without draining your campaign funds too early. 🕓 4. The Takeaway Provisional = Speed & Flexibility Non-Provisional = Strength & Enforceability Start small, but start right. Your patent strategy should grow with your product — just like your campaign evolves from a concept video to real-world production. China IP Gateway, Peter Lin, IP之道, Intellectual Property China, Trademark Registration China, Patent Filing China, Brand Protection, OEM Risk, China Manufacturing, IP Strategy #ChinaIP #TrademarkChina #BrandProtection #IntellectualProperty #PeterLin #ChinaIPGateway #OpenPTO #IPStrategy https://www.linkedin.com/pulse/provisional-vs-non-provisional-patent-applications-which-peter-lin-ivqfc

China IP Guides

By Peter Lin/ On 19 Mar, 2026

What a China Manufacturing Agreement Should Say About Tooling and Molds

When foreign companies think about manufacturing agreements in China, they often focus first on pricing, quality standards, lead times, inspection rights, or payment terms. Those terms are important. But one of the most under-discussed areas is also one of the most practical: tooling and molds. If your product depends on customized molds, tooling, fixtures, or manufacturing-specific production assets, then your agreement should not treat them as a side note. Why This Issue Matters So Much Many founders assume tooling is simple: “We paid for it, so it is ours.” Commercially, that sounds reasonable. Contractually and operationally, that assumption is often too thin. If tooling language is vague, disputes can arise around issues such as:who legally owns the mold or tool; where it can be stored; whether it can be reused; whether it can support production for other customers; what happens if the relationship ends; whether the factory must return, destroy, transfer, or preserve it.That is why tooling should not sit in the agreement as a casual reference. It needs explicit handling. The Real Question The real question is not: “Did we mention molds somewhere?” The better question is: “If the factory relationship goes wrong, have we clearly defined what the tooling is, who controls it, what it can be used for, and what must happen next?” That is the standard to aim for. What Foreign Brands Often Miss Foreign brands often miss three practical realities. 1. Tooling is not just a physical asset It is often a gateway to product replication, replacement production, and commercial dependency. 2. Payment does not solve every downstream issue Even if you paid for the mold, a weak agreement may still leave key questions unclear. 3. Tooling risk connects to broader IP risk If your product design, structural features, branding, or production know-how are already exposed, tooling can become the operational bridge between your idea and someone else’s production power. What a Good Tooling Clause Should Actually Cover A strong manufacturing agreement does not need dramatic wording. It needs practical clarity. Clear identification The agreement should identify what tooling, molds, fixtures, or custom production assets are covered. Ownership It should clearly state who owns them, and not leave that point to commercial assumption. Permitted use The agreement should define what the factory can use the tooling for — and what it cannot. Storage and control Where is it stored? Who has access? Can it be moved? Can it be duplicated? Can subcontractors touch it? Maintenance and condition Who is responsible for routine maintenance, repairs, and condition records? End-of-relationship handling If the project stops, what must happen next? Return, transfer, preservation, destruction, or supervised handover should not be left vague. Misuse consequences If tooling is used outside the agreed scope, the agreement should make the consequences clear. Why Tooling Terms Cannot Be Separated from IP Terms Tooling language becomes much stronger when it is not drafted in isolation. Brand connection If the tooling is used to produce goods carrying your brand, then trademark thinking matters too. If branding is already visible in factory-side work, review China Trademark alongside the contract. Product connection If the tooling embodies product structure or technical know-how, then patent timing may also matter. In some cases, China Patent Filing Support should be part of the conversation before production deepens. Supplier-stage contract connection If you are still early in the supplier relationship, China NNN & OEM Agreements is often the right place to start, especially where disclosure, non-use, and supplier-stage control are not yet properly locked down. Common Weak Drafting Patterns Here are some weak patterns I often see. “Tooling belongs to the buyer” — full stop This is better than silence, but still may not say enough about access, use, duplication, movement, or end-of-project handling. Tooling buried inside a generic property clause If tooling is commercially important, it should not be hidden in one broad sentence. No termination mechanics If the relationship breaks down, vague ownership language alone may not tell the parties what happens next. No link to subcontracting If the factory can subcontract freely without careful limits, tooling control can become much harder in practice. When This Becomes Urgent This issue becomes urgent when:the product requires custom molds or fixtures; tooling cost is significant; the factory relationship is becoming exclusive or strategically important; second-source manufacturing may later be needed; the product has meaningful IP value; you are already moving into pilot or mass production.At that stage, tooling should not remain a side conversation between engineering and purchasing. It should be part of the legal and IP structure. A Better Practical Approach A better approach is to review tooling and mold terms through three lenses at once: Commercial lens What production flexibility do you need later? Legal lens What rights and obligations need to be explicit now? IP lens How does tooling connect to product replication, brand control, and technical exposure? That is usually the conversation that produces an agreement with real business value. Frequently Asked Questions If I paid for the tooling, is that enough? Not always. Payment helps, but it does not automatically answer every question about use, control, duplication, storage, or post-termination handling. Does this only matter for large production runs? No. In some cases, it matters even more in early-stage manufacturing because the business is still vulnerable and the production structure is not yet mature. Should I handle this before placing the first real production order? Very often, yes. Once production dependence increases, weak tooling language can become harder to fix. Final Thought A tooling clause is not a minor appendix for engineering projects. In many China manufacturing relationships, it is one of the most practical control points in the entire agreement. If your product depends on molds, tooling, or custom production assets, the safest time to define ownership, permitted use, and exit handling is before those assets become the backbone of your manufacturing relationship. If this is your current stage, start with China NNN & OEM Agreements or Talk to Us.

Practical Answers

By Peter Lin/ On 12 Dec, 2025

Adult Products Often Get Rejected for Patents in China—Why?

China's Patent Scene: Huge Opportunities, but Article 5 is a Hidden Minefield China's paAdult productsploding—global $50B by 2027 (Statista), with China leading manufacturing （Dongguan & Shenzhen）. Yet Article 5 of the Patent Law is a silent killer, blocking grants for inventions seen as violating "social morality" or public interest. Designs saw a 15% rejection spike in 2024 due to visual cues, but utility and invention patents can stay steady if drafted right. The issue? Examiners tag products as "non-medical artificial sexual substitutes," sparking morality checks. From my examiner chats and database dives, if descriptions scream "intimate," initial reviews flop. Article content Kegel Exercises: Your "Medical Shield" to Bypass Article 5 How to flip it? Kegel exercises are your secret weapon. Developed by Dr. Arnold Kegel in the 1940s, these pelvic floor workouts help millions with incontinence, postpartum recovery, and quality of life (PubMed studies). In patents, a line like "vibration modes simulate Kegel contractions for muscle strengthening" shifts from "toy" to "health aid." Why? The 2023 guidelines say non-medical substitutes violate morals; Kegels provide real medical evidence (GB/T 14895-2010 standard), and examiners nod at that. In a case I handled, this turned a "no" into approval—but don't fake it; unsubstantiated claims risk fines. Article content patent illustration Drafting Magic: Lessons from a Smooth Success Case Drafting is the real art. Take CN223666103U, an "insertable electric massager" granted December 2025 without issues—just 10 months. It nailed it by focusing on "vibration mode indicators" over intimacy. CNIPA data shows medical-framed patents hit 85% approval in 2024, vs. 40% for pure adult ones. Here's their techniques vs. pitfalls I've fixed Article content This echoes trends: 2023 guidelines stress public acceptance—Taobao sales or Shanghai expos aren't "immoral." But controversies persist: Unproven health claims lead to rejections. Examiners aren't anti-innovation; they just need proof it's beneficial, not boundary-pushing. For Global Players: Stack US/EU Patents For global players, stack US/EU patents—USPTO's lenient on health claims, perfect for Amazon enforcement. Faced challenges in sensitive tech patents? Share below—I'd love your stories! #PatentStrategy #AdultWellness #ChinaIP #KegelInnovation #EntrepreneurJourney Key Citations: China National Intellectual Property Administration (CNIPA) Database Statista Adult Wellness Market Report PubMed on Kegel Exercises Beijing IP Court Case (2019) Jing 73 Xing Chu 3870 2023 Patent Examination Guidelines For more article, visit our Linkdedin newsletter: https://www.linkedin.com/newsletters/china-ip-gateway-7392039659566153728/

Insights

By Peter Lin/ On 30 Nov, 2025

China Takes Half of the World's Patent Filings — What the Data Really Means for Global Innovation

But instead of only looking at the number, I want to break down the structure behind it — and what it signals for global innovation. Here are the three essential shifts I think matter most. Article content The Way of IP 🔍 1. Why are China’s filings so high? It’s not “volume chasing” — it’s market structure + national strategy. In 2024, Chinese applicants filed 1.8 million invention patents. This isn’t a coincidence. Two forces are driving it: ① China’s massive domestic market demands rapid innovation. Fast product cycles Dense supply chains High competition across industries Patents act as a key defensive moat See content credentials Article content In such a large internal market, domestic filings will naturally concentrate. ② China is actively positioning high tech as the next economic growth engine. This part is important. China’s national strategy is now heavily oriented toward innovation, advanced manufacturing, and deep tech. 📌 So the high numbers are not an “anomaly” — they are the outcome of both structure and policy. 🔍 2. Why is China’s overseas filing ratio lower? It reflects different economic models, not different levels of ambition. This is the most misinterpreted WIPO number: China: 6.9% of filings go overseas US: 46% Japan: 43% Germany: 51% People often jump to conclusions, but the explanation is simpler: China’s innovation is anchored in a huge domestic market. Companies build their defensive position at home first, then expand overseas based on business needs. US, Japan, and Europe operate with global supply chains from day one. Their IP naturally follows international markets. 📌 These are two different innovation pathways — not “better or worse.” 🔍 3. From my own work at openPTO: China’s overseas patent activity is clearly accelerating. Beyond the statistics, my daily work gives me a very practical view: More Chinese companies are globalizing than ever before PCT filings and US/EU/JP national filings are rising steadily Overseas litigation risks are pushing companies to plan ahead Clients are shifting from “domestic protection only” → to “global positioning” 📌 China’s global patent layout is not slow — it’s in its acceleration phase. The next 3–5 years will be a structural turning point. 🌍 What does this mean for global innovators? Two opportunity windows are opening: ✓ Opportunity 1: Cross-border technical collaboration will grow rapidly. As Chinese companies globalize, we will see more: Joint R&D Co-patenting Technology licensing Standard-setting collaboration International manufacturing partnerships ✓ Opportunity 2: Demand for cross-border IP services will enter a long growth cycle. This directly affects: Patent attorneys IP lawyers Technology startups R&D institutions Investors China’s global expansion unlocks a new layer of IP demand. 📌 Key Takeaways China’s filing volume is driven by both market scale and national innovation strategy The lower overseas ratio reflects a stage of development, not a weakness China’s international filings are now clearly accelerating Global innovators will see increasing collaboration and service opportunities In the next issue, I’ll cover an equally important question: Why is China number one in “patent density,” yet still has a relatively small share of multi-jurisdiction patent families? And what does that mean for the next decade of global tech competition?

Practical Answers

By Peter Lin/ On 15 Dec, 2025

How Much Can You Really Amend Claims When Entering China via PCT?

One of the most common questions I hear from foreign inventors entering China via PCT is: "I want to adjust my claims before the Chinese prosecution starts — how much can I actually change?" The honest answer is: more than you think in terms of scope reduction, but far less than you think in terms of new content. And the boundary between the two is where applicants get into trouble. What the Rules Say When entering China's national phase via PCT, you are technically allowed to amend your claims. CNIPA accepts amendments at national phase entry under China's Patent Law and the Implementing Regulations. But those amendments are subject to a fundamental constraint: No amendment may introduce subject matter that goes beyond the original disclosure — meaning the content of the international application as filed. This rule appears in the Chinese Patent Law broadly, and CNIPA examiners apply it consistently. The relevant standard is "beyond the original disclosure," not just "beyond the original claims." That distinction matters significantly. What You Can Do: The Permitted Range Within the no-new-matter rule, the following types of amendments are generally permitted: Narrow the independent claims. You can import limitations from your dependent claims into an independent claim, making it narrower and more specific. This is the most common and useful type of amendment at national phase entry. Delete claims entirely. Removing claims — whether to reduce fees (claims beyond 10 are surcharged) or to simplify prosecution — is permitted. You cannot, however, re-add them later without going through a formal amendment process. Combine dependent claims into a new independent claim. If a combination of features from two dependent claims is fully supported by your specification, you can combine them into a new independent claim. This is useful for creating a stronger fallback position. Correct obvious translation errors. If your Chinese translation contains an error that results in a narrower scope compared to the original PCT application, you can request correction — but only if the correction is directly and unambiguously supported by the original international filing. What You Cannot Do: The Hard Line Add features not in the original specification. If a feature was never described anywhere in your international application — not in the claims, not in the description, not in the drawings — you cannot add it to your claims at national phase entry. CNIPA will reject the amendment as introducing new matter. Broaden claim scope beyond what was disclosed. You cannot broaden an independent claim to cover subject matter that was described only as a narrower sub-case in the original application. For example, if your specification only describes an embodiment using "copper wire," you generally cannot amend the claim to read "conductive wire." Import content from prior art or external sources. Even if something is technically compatible with your invention, it must be described in the original application to be incorporated into claims. The Common Mistake: Over-Relying on What's in the Specification I see this pattern regularly: an applicant wants to amend their China Patent claims to add a feature that was mentioned in the background section or in a general statement of advantage — but never specifically claimed or described as a component of the invention. CNIPA examiners draw a tight circle around "original disclosure." A feature in the background section is not always treated as part of your invention disclosure. A general admissibility statement ("the invention may also include...") without a specific embodiment is often not enough to support a claim amendment. The lesson: your specification's disclosure quality, written at the time of the original PCT filing, determines your amendment latitude in China — often 28+ months later. Practical Strategy: Front-Load Your Disclosure The best way to maximize your amendment options in China is to draft your international application with China specifically in mind:Include multiple specific embodiments in the description, not just one or two. Write out dependent claims carefully — each one represents a fallback position you can later elevate into an independent claim. Avoid overly narrow "examples" without broader claim support language.A China Patent Attorney can review your existing PCT application and identify which amendments are genuinely available to you before national phase entry — and which wishlist items are off the table. What About Article 34 Amendments? Before entering the national phase, you may also have used PCT Article 34 to request preliminary examination and amend claims internationally. Those amendments, if already incorporated into your PCT application, become the new baseline for China national phase entry. However, China is not obligated to accept them if they introduced new matter by PCT standards — and CNIPA performs its own assessment.Need to review your PCT application before China national phase entry? Our China Patent specialists can audit your pending PCT applications and advise on amendment strategy. Or speak directly with a China Patent Attorney about your specific filing.

Insights

By Peter Lin/ On 01 Dec, 2025

How to Protect Your Idea Quickly in China: A Personal Note from the Train

🇨🇳 Why Dual Filing Works in China A utility‑model patent covers structural or mechanical improvements and typically grants within about six months. Think of it as a quick shield. It gives you an enforceable right early, so you can show investors, partners and even Customs officials that your design is protected. Meanwhile, you simultaneously file a full invention patent, which takes longer but provides stronger, broader protection once it is granted. By starting them both together, you protect yourself at two speeds: fast and long‑term. Once the invention patent is issued, you can withdraw the utility model to avoid double. 🔍 Does it suit every innovation? This strategy shines for hardware or structural improvements—think product casings, mechanical components, new configurations or machinery. For software, algorithms or purely digital inventions, you still need to go through the standard invention patent route (which takes time), and other IP tools like copyright or trade secrets may be more appropriate. 🚀 My advice to fellow founders Don’t wait for perfection. File early, iterate quickly. In China’s “first to file” system, speed matters. Leverage the fast and slow lanes. A utility model buys you time; the invention patent keeps your protection strong for the long run. Tell your story. Investors and partners respond better when you can show that you’ve taken proactive steps to secure your IP, rather than saying “we’re working on it.” As someone who’s helped many startups navigate this path, I know first‑hand how disheartening it is to see a good idea copied simply because the filing happened too late. Don’t let that be your story. If your products touch China, your protection strategy should too. Feel free to reach out if you’d like help planning your IP filings or understanding which options best fit your product. Safe travels and safe ideas!

Insights

By Peter Lin/ On 08 Jan, 2026

PCT Entry into China: Lessons from my 45-day Journey with Sarah, a British Inventor

Sarah contacted me in October. She was 31 months from her priority date — nine months before her Chinese national phase deadline — and she had been putting off the conversation because she wasn't sure she could afford it. Over the next 45 days, we worked through every dimension of her China patent decision together. What follows are the lessons that came out of that process. They apply to almost any foreign inventor considering PCT entry into China. Day 1–7: Understanding what you're actually entering Sarah's PCT application had been filed in the UK. She had used a UK attorney, received a PCT international search report with some objections, and largely moved on. When I pulled up the document, the claim set was ambitious — twelve independent claims, broad functional language, coverage across three distinct embodiments. The first lesson came immediately: the document you filed under the PCT and the document that will survive Chinese examination are often two very different things. CNIPA examiners work from the Chinese translation. They apply Chinese patent law, which has its own interpretations of terms like "substantially" and "approximately." The international search report had flagged prior art that, in a Chinese examination context, would likely cause issues on at least four of her independent claims. Lesson 1: Start the China-specific analysis at least 12 months before your deadline — not 6. Day 8–20: The translation question Sarah had assumed we would simply translate the existing PCT document into Chinese. What she hadn't considered is that translation is both a linguistic and a legal act. We spent two weeks working through her Chinese translation with a technical translator who specialised in UK-origin engineering language. Several terms in her specification had multiple plausible Chinese equivalents — and each choice carried a different scope implication under Chinese patent law. One term — a surface treatment described as "polished to a smooth finish" — had a literal Chinese rendering that CNIPA examiners would likely interpret as requiring a specific surface roughness measurement. We rewrote the passage to describe the functional outcome rather than the finishing process, backed by an example from her drawings. Lesson 2: Translation is a strategic decision, not just a language exercise. Day 21–35: Claim strategy for CNIPA We narrowed the claim set from twelve independent claims to four. This was not a retreat — it was a focus. The four we kept mapped directly to her commercial product, covered the manufacturing process she was actually using, and had the strongest prior art position. The other eight claims were not abandoned. They were moved to dependent claims, giving us options during examination while reducing the surface area for initial rejection. Lesson 3: Fewer, stronger independent claims outperform many weak ones at CNIPA. Day 36–45: The filing decision On day 36, Sarah asked the question I hear from almost every foreign inventor: "Do I actually need this patent in China, or am I just filing because that's what you do?" It is a fair question. Her product had no current distribution in China. Her manufacturer was in Taiwan. But her market projections showed Southeast Asia as her next expansion target — and several of those markets are increasingly influenced by Chinese supply chains. A defensive filing by a Chinese competitor, using her unprotected technology, could lock her out. We filed. Not out of habit, but because the risk calculus was clear: the cost of entry was modest compared to the exposure she would face if a Chinese manufacturer reverse-engineered her product and filed a defensive utility model around it. Lesson 4: The question is not whether to file — it's whether to file strategically. What the 45 days taught me Sarah's situation was not unusual. Most foreign inventors arrive at the China national phase deadline with documents that haven't been reviewed for Chinese-specific risk, translations that haven't been stress-tested against CNIPA's reading habits, and claim sets built for the PCT international phase — not for a Chinese examination. The 45 days we spent together compressed what should have been years of forward planning into a focused, defensible process. What came out the other side was a China patent application built for China — not a PCT application that happened to be filed there.If you have a PCT deadline approaching and want to think through your China entry before the clock runs out, our team can review your application, identify the specific risk points, and help you define a filing strategy that fits your business. Learn more about China patent filing or speak directly with a China patent attorney about your timeline.

Practical Answers

By Peter Lin/ On 08 Dec, 2025

Paris Convention vs. PCT in China: A Critical Difference Most Inventors Miss

Last year a Dutch hardware startup came to me eight months after filing their first patent in the Netherlands. They had a working product, a potential distributor in Shenzhen, and a growing sense that they should probably protect something in China. Eight months was still within the Paris Convention window. But when I asked whether they had a finalized Chinese translation of their specification ready to file, the answer was no — and their September launch timeline meant four months were the most they could realistically get. That conversation is where the Paris Convention versus PCT question becomes real. In theory, both routes let you claim your Netherlands filing date as your priority date in China. In practice, only one of them gave this team the time they actually needed. The two main options are the Paris Convention direct route and the PCT route, and in China specifically, there are differences that can significantly affect your cost, timeline, and final patent scope. The Basic Framework Both routes allow you to claim the priority date from your original domestic filing when you eventually file in China. That priority date matters enormously in China's first-to-file system — it determines whether you beat a competitor to protection rights.Paris Convention route: File directly in China within 12 months of your first filing date. PCT route: File an international PCT application (within 12 months of your first filing), then enter China's national phase within 30 months of your priority date.That extra 18 months the PCT route provides is not just a filing convenience. It's a strategic window that most inventors underuse. The Critical Difference Most Miss Here's what I see inventors get wrong again and again: When you file directly into China via the Paris Convention route, you must have a fully translated Chinese application ready within 12 months. That means your specification, claims, and abstract — all in Chinese — submitted together with your filing fee. For an early-stage startup, 12 months from first filing is often not enough time to finalize your design, assess the Chinese market, or arrange quality translation. The PCT route, by contrast, lets you delay that commitment. You file the international PCT application in your own language (typically English), and the Chinese translation only needs to be submitted when you enter the national phase at month 30. That's an additional 18 months to refine your claims, secure funding, or assess whether China is worth the investment. Why China Specifically Amplifies This Gap Many PCT member countries accept English filings even at national phase entry. China does not. CNIPA requires a full Chinese translation of your application at national phase entry. A poor translation can cost you claim scope — permanently. Under Chinese patent practice, if there is a discrepancy between the original PCT application and the Chinese translation, CNIPA will generally rely on the Chinese translation as the basis for examination. This makes translation quality a strategic issue, not just a clerical one. The extra time the PCT route provides lets you commission and review a professional-grade translation — rather than rushing one through in the final weeks before a 12-month Paris Convention deadline. The Trap: Assuming PCT Is Always Better PCT is not universally superior. Here's when the Paris Convention direct route makes more sense for China Patent filings:You are confident about the Chinese market now. If you have a distribution partner, manufacturing arrangement, or real commercial activity in China within 12 months, you may not need the extra time. Your technology is simple and the application is short. Translation cost and risk are proportional to specification length. A 10-page utility application translates much faster and more reliably than a 100-page biotech filing. You want to avoid PCT fees. PCT filing has its own international fee structure. If you're early-stage and China is your only international target, the direct route may be cheaper overall.What a China Patent Attorney Will Actually Tell You When I advise clients as a China Patent Attorney, this is the question I always ask first: How confident are you today about what your Chinese patent needs to protect? If the answer is "very confident, and we have a product ready to launch," the Paris Convention route is often fine. If the answer is "we think China matters but we're still refining the product," the PCT route is almost always the right choice — not for the extra protection it adds, but for the strategic flexibility it buys. A Simple Decision FrameworkSituation Recommended RouteProduct is final, China launch within 12 months Paris Convention directStill refining design or claims PCT → China national phaseMultiple countries beyond China PCT (efficiency of one filing)Budget-constrained, China only Paris Convention (lower upfront cost)Complex specification, translation risk PCT (more time for quality translation)Have questions about your China patent filing strategy? Explore our China Patent services or speak with a China Patent Attorney about whether Paris Convention or PCT is the right route for your situation.

Practical Answers

By Peter Lin/ On 12 Dec, 2025

PCT Patent Entry into China: A Cost Lock-In Mechanism Many Applicants Overlook

There is a moment, usually around month 28 or 29 of your PCT application's life, when your China IP strategy becomes a cost reality. The application that started as an idea — and grew through drafting, international search, and maybe some Article 19 amendments — now has to become a paid-up Chinese patent prosecution. What many applicants find surprising is how much of that cost was already locked in by decisions made much earlier. This is what I call the cost lock-in mechanism of PCT entry into China. What Gets Locked In at National Phase Entry When you enter China's national phase, CNIPA's official fees are calculated based on the application as it stands at entry. Specifically: 1. Claim count. China charges a per-claim surcharge for every claim beyond the first ten. If your PCT application has 25 claims, you're paying surcharges on 15 of them upfront — before a single examination action. This is calculated from the claims in your Chinese translation at the time of national phase entry. 2. Page count for specification. China's official fee structure also includes charges based on application length above a base threshold. A long international specification — common in US and European biotech or software filings — translates to elevated fees. 3. Translation volume. Unlike most Western patent offices, CNIPA requires a complete Chinese translation of your entire application at national phase entry. The word count in your international specification drives translation costs directly. A 200-page biotech specification translated at professional patent rates is a significant line item. 4. Number of independent claims. Prosecution strategy in China often hinges on independent claims, and CNIPA's fee structure treats them differently from dependent claims. Applicants with multiple independent claims per claim category (product + method + use) face compounded costs. Why "Lock-In" Happens in Practice These cost drivers are not surprising in isolation. What makes them a lock-in mechanism is that they were all set at the time your international PCT application was drafted — often 18 to 28 months before you ever think about China costs. The original PCT drafter may have been a US firm optimizing for a large US claim set. The specification may be 150 pages because that's what a US biotech application requires. The claims may number 30 because that's what a US prosecution strategy demands. None of that is wrong for the US. But entering China's national phase with that original application, unchanged, means you're paying for a US-optimized filing in a system with a very different fee structure. The Three Levers You Can Still Pull Even though costs are largely locked in by the original application, you do have options to reduce them — if you act before national phase entry. Lever 1: Amend claims before entry. Under PCT provisions and China's national phase rules, you can amend your claim set when entering the national phase. Reducing from 25 to 10 claims before filing the Chinese translation eliminates surcharges on 15 claims from day one. Work with a China Patent Attorney to identify which claims are commercially necessary in China and which are redundant for your specific enforcement context. Lever 2: Trim the specification. If there are entire sections of your specification that are irrelevant to your China commercial strategy — detailed manufacturing examples for processes you don't use in China, regulatory guidance for systems not sold there — you may be able to reduce the document length without affecting claim support. This is technically sensitive work and needs expert review, but can materially reduce translation and page-count fees. Lever 3: Time your filing carefully. CNIPA applies fee rates based on the filing date. Fee schedules are periodically updated. While this is not always a controllable variable, large multinationals with portfolios sometimes time batch filings to a known fee period. A Cost Estimate to Make This Concrete For a typical mechanical or hardware China Patent application entering via PCT with 20 claims and a 50-page specification, you're typically looking at:Official filing fee: ~RMB 950 base Claim surcharges (10 claims over base × RMB 150): RMB 1,500 Translation (50 pages × professional rate): RMB 5,000–12,000+ Professional services (national phase formalities, claim strategy): variableCompare that to the same application trimmed to 10 claims: the surcharge line drops to zero. Over a portfolio of 20 applications entering China in a single year, that's a meaningful difference. The Upstream Solution The best time to manage China national phase costs is not at month 29. It's at the drafting stage, when you structure your PCT application with China's fee logic in mind. This doesn't mean writing a weaker patent. It means structuring claims and specifications in a way that is both strong for the US and efficient for China — not identical, but compatible.Ready to plan your China national phase entry? Our China Patent team works with applicants at every stage of the PCT timeline. Or speak with a China Patent Attorney to review your pending applications before the 30-month deadline.

Practical Answers

By Peter Lin/ On 17 Dec, 2025

A Simple Way to Cut China Patent Costs When Using PCT — Without Giving Up Protection

Let me say something directly: most foreign companies entering China via PCT are paying more for their Chinese patents than they need to. Not because of unfair fees, and not because their technology is especially complex — but because nobody has walked them through the specific cost levers that exist in this system. This is a practical guide to those levers. Understanding Where China Patent Costs Come From Before you can cut costs intelligently, you need to know where they go. For a typical China Patent application entering via PCT, the main cost buckets are:Official CNIPA fees: Filing fees, claim surcharges, examination fees Translation fees: Chinese translation of the full specification, claims, and abstract Professional services: Attorney or agent fees for formalities, claim strategy, and prosecution management Office action responses: Costs that arise if CNIPA examiner raises objections after filingThe first three are largely determined by what you submit at national phase entry. The fourth depends on how well you handled the first three. Lever 1: Reduce Claims to 10 or Below This is the single most effective cost reduction available to most applicants, and it's often overlooked because it requires a strategic decision rather than just a procedural one. China charges an extra fee for every claim beyond the first ten. At the current CNIPA fee schedule, each additional claim costs RMB 150 extra in filing fees — and this is per claim, per application, at entry. For an application with 25 claims, that's RMB 2,250 in surcharges before prosecution even begins. Across a portfolio of 10 applications, you're looking at RMB 22,500 in preventable costs. More importantly: reducing claims forces a useful discipline. Which 10 claims actually capture what you need to protect in China? That forced prioritization almost always produces a stronger prosecution strategy. Work with a China Patent Attorney to review which claims are genuinely necessary for Chinese market protection and which are redundant or commercially irrelevant for this jurisdiction. Lever 2: Use the International Search Report to Pre-Empt Office Actions One of the underutilized advantages of PCT is that you receive an International Search Report (ISR) — typically by month 16 from your priority date — that identifies prior art relevant to your claims. Most applicants read this report once and file it away. A smarter approach: use the ISR to narrow or differentiate your claims before China national phase entry. If the ISR identified prior art that your current independent claim reads on, addressing that in your Chinese claim set before entry means you avoid the same objection being raised by a CNIPA examiner six months into prosecution — which costs you an office action response fee, attorney time, and months of delay. Pre-emptive amendment based on ISR findings is one of the clearest, lowest-cost interventions available before the 30-month deadline. Lever 3: Trim the Specification Length Where Possible China's official fees include a per-page component above a base threshold. More consequentially, translation costs are purely volume-driven. Review your international specification with a China-specific lens:Are there multiple detailed examples that describe the same embodiment with minor variations? Consolidating these reduces page count without affecting claim support. Are there sections discussing prior art in excessive detail? These may be necessary for US prosecution but add translation cost in China. Are there drawings that replicate each other with minimal difference? Each drawing page has a cost.Trimming even 20–30% of specification length can produce meaningful savings, especially for large mechanical or pharma filings where descriptions commonly run 100+ pages. Lever 4: Sequence Your Portfolio Entry Strategically If you have multiple PCT applications approaching the 30-month deadline in the same period, the sequence and grouping of national phase entries matters. Some applicants enter all applications simultaneously, paying a large lump sum of fees and translation costs in a short window. Others sequence entries across 3–6 months to smooth cash flow and allow claim review on each application before committing. More importantly: if two related applications in your portfolio cover overlapping technology, entering them simultaneously allows a single attorney review session to address both claim strategies — reducing professional fee overhead compared to treating each in isolation. What You Don't Have to Give Up The goal here is cost efficiency, not weakened protection. A 10-claim application with three tight independent claims and seven well-structured dependent claims can be more defensible in Chinese courts and licensing contexts than a sprawling 30-claim application that's never been tested. Chinese IP enforcement increasingly focuses on specific, clean claims. Clarity and focus are assets in China's court system and in licensing negotiations — not liabilities.Want a pre-entry cost review for your PCT applications? Our China Patent team provides claim strategy and cost analysis before your 30-month deadline. Speak with a China Patent Attorney today.

Practical Answers

By Peter Lin/ On 22 Dec, 2025

If a Translation Error Narrows Your Patent in China — Will CNIPA Be Sympathetic?

Here is a scenario I've seen damage Chinese patent portfolios more than once: A foreign company enters China's national phase via PCT. The Chinese translation is done quickly, under deadline pressure, without sufficient technical review. A single term — a materials specification, a functional description, a dimensional range — is translated too narrowly. The original PCT application covers "metal alloy"; the Chinese translation reads "aluminum alloy." Now the examiner works with the Chinese text. The granted patent is limited to aluminum alloy. The company's actual product uses a titanium alloy. The question everyone asks afterward: Will CNIPA let us correct it? The honest answer: sometimes, but the standard is strict and the window is short. How CNIPA Treats Translation as the Binding Text This is the foundational issue. Under China's patent system, the Chinese translation you submit at national phase entry becomes the operative text for examination purposes. CNIPA does not conduct examination on the original English (or other language) PCT application. The Chinese document is what examiners read, cite, and base their assessment on. This is different from some other jurisdictions where the original application remains the reference. In China, if there is ambiguity or conflict between the original PCT filing and the Chinese translation, the Chinese translation governs — unless you successfully obtain a correction. The Correction Mechanism: What Exists China's Implementing Regulations do provide a mechanism for correcting errors in translations submitted at national phase entry. The relevant provision allows an applicant to request correction of an obvious translation error when:The mistake is clearly an error — not a judgment call or intentional drafting choice, but an actual mistranslation. The correction would restore the Chinese text to accurately reflect the original PCT application. The correction does not introduce subject matter that goes beyond the original PCT application as a whole.The third condition is the critical one. If the mistranslation was a narrowing of the original PCT disclosure, correcting it should not violate the no-new-matter rule — because you're restoring the original scope, not adding something new. Where the Process Gets Difficult In practice, "obvious translation error" is interpreted narrowly by CNIPA examiners. Here is where applicants run into problems: The error is arguable, not obvious. If there are two plausible Chinese translations of a term and one happens to be narrower, CNIPA may view the narrower translation as a reasonable choice rather than a clear error. "Reasonable choice" is not correctable. "Clear mistranslation" is. The correction window has passed. CNIPA has a time limit for requesting translation corrections. Applicants who discover a translation problem late in prosecution — or after grant — have very limited options. Post-grant correction is even harder. The correction requires supporting evidence. To successfully correct a translation error, you typically need to provide the original PCT text (in the original language), a side-by-side comparison, and often a declaration or explanation showing that the Chinese translator deviated from the source. Without this documentation, the request is unlikely to succeed. Is CNIPA Sympathetic? Straightforwardly: less than you might hope. The Chinese China Patent system is procedural and examiners work within defined standards. They are not adversarial, but they are also not inclined to exercise generous discretion where the rules are not clearly on your side. CNIPA will review a well-documented correction request for an obvious error fairly. What it will not do is accept borderline arguments, overlook timing requirements, or allow corrections that stretch into new matter territory even slightly. The applicants who succeed with correction requests are those who:Identify the error early (before or during examination, not after grant) Have kept the original-language PCT application and the Chinese translation in a form that allows direct comparison Can demonstrate the error is unambiguous — not one of two reasonable interpretations Work with a China Patent Attorney who understands CNIPA's correction procedure and documentation requirementsThe Real Lesson: Prevention Over Remedy Every practitioner who has been through a translation correction request with CNIPA knows the same thing: the process is difficult, expensive, and uncertain. Even a successful correction takes months and significant attorney time. An unsuccessful correction leaves you with the narrowed patent permanently. The correct response to translation risk is to prevent it, not to plan for correction. Here are the specific linguistic categories where narrowing errors most commonly occur in Chinese patent translation: Functional language. English claim language like "configured to" or "operable to" has no direct Chinese equivalent with the same legal weight. Translators sometimes substitute 用于 (used for) which can be read as a use limitation rather than a structural feature. This subtly narrows scope. Numerical ranges. Ranges like "between 10 and 50 mm" or "at least 80%" are sometimes rendered with the wrong boundary interpretation in Chinese (including or excluding endpoints). These discrepancies compound in prosecution when examiners apply the Chinese text literally. Material and component generalizations. "Conductive material" translated as "金属" (metal) instead of "导电材料" (conductive material) — this exact type of narrowing gives rise to the titanium alloy scenario described above. In chemistry and materials patents, every noun is a potential claim scope trap. Method claim verbs. Verbs describing process steps — especially in pharma, biotech, and software — often have multiple Chinese translations with different levels of specificity. The broader English verb may not have a direct Chinese cognate. The practical prevention checklist:Allocate 10+ business days for complex specifications, with technical review Have a bilingual patent professional review the Chinese translation of your key claims before submission Work with a translation provider that has subject-matter expertise, not just general technical translators Review the translation yourself if you have Chinese language capability — at minimum, run the independent claims through a reverse translation and compareConcerned about translation quality in your China patent applications? Our China Patent team reviews PCT translations before national phase entry and handles CNIPA correction procedures when needed. Speak with a China Patent Attorney about protecting your claim scope from the start.

Insights

By Peter Lin/ On 05 Jan, 2026

Two Inventors. Two Views on China Patents. One Hard Reality.

I've had this conversation more times than I can count. Two different inventors, two completely different beliefs about China, and one outcome that neither of them expected. The first inventor — call him Marco, a German engineer — came to me after his startup's sensor technology started appearing in Chinese online stores. He had never filed in China. His reasoning: "We know China is a copycat market. We focused on protecting in Europe and the US." The second inventor — call her Liu Wei, a Chinese-American founder — came to me three months before her Kickstarter launch wanting to file patents in every major jurisdiction simultaneously, including China, "just to be safe." Both of them were acting on convictions. Both of them needed a different conversation than the one they expected. The "China doesn't respect IP" myth Marco's assumption is common, and it is becoming less accurate every year. China processed over 1.5 million patent applications in a single year. Its courts are increasingly ruling in favour of foreign IP holders. Multinationals from Germany, Japan, and South Korea now rely on Chinese patent filings as a core part of their China strategy — not because they are optimistic, but because they have done the maths. When Marco's technology appeared on Taobao, his options were limited. A cease-and-desist letter from Europe meant nothing to a Shenzhen supplier. Without a Chinese patent, his leverage was near zero. The "protect everything everywhere" trap Liu Wei's instinct was the opposite — and also wrong, but for a different reason. Filing simultaneously across five jurisdictions before her invention claims were finalised would have locked in broad, untested language everywhere. In China specifically, where examiners apply strict "no new matter" rules, you cannot go back and strengthen claims after filing. I suggested she use the PCT route first, use the national phase entry window to refine her claims, and enter China when she had a clearer picture of the manufacturing landscape and the competition. The hard reality Neither extreme works. "Don't bother with China" leaves you exposed in the world's largest manufacturing hub, with no legal recourse if a supplier copies your design or a competitor files a defensive patent around your technology. "File everywhere immediately" creates a patchwork of broad, expensive, under-optimised patents that are difficult to enforce and costly to maintain. What works is strategic China Patent filing: understanding which claims need China coverage, when to file, via which route (PCT or Paris Convention direct), and what IP assets beyond patents — NNN agreements, trademarks, design registrations — form the protection perimeter. What happened to Marco and Liu Wei Marco's case was not lost. We identified a utility model filing path that, while not matching his original broad claims, established a prior art position and gave him a platform to negotiate with the Shenzhen supplier. The lesson was expensive. But it wasn't terminal. Liu Wei launched on schedule. She entered China's national phase at month 28 with a claim set refined through the PCT international phase examination. Her granted Chinese patent, when it came, was narrower than her original filing — but it was exactly the right scope for the product she had actually launched. The difference one conversation makes If you're an inventor or a startup founder approaching China with either of these two views, I'd like to offer a third: China is not a threat to be ignored, and it's not a jurisdiction to approach through fear. It's a market, a manufacturing centre, and an IP arena — one that rewards preparation and punishes assumptions. If you're unsure which view has been shaping your decisions, that's a good place to start.Ready when you are. Our China patent team can assess your situation and map out the most defensible filing path for your technology. Speak with a China patent attorney to get a direct read on where you stand.

Entering China via US PPA: Don't Let These 3 Details Ruin Your Patent Strategy

Detail 1: The 12-Month Deadline Is Absolute — and It Runs from the PPA Date, Not the Non-Provisional

Detail 2: A Weak PPA Creates Unsupported Claims in China

Detail 3: PCT Is Your Bridge — and It Has Its Own Timing Logic

Why These Details Matter Specifically in China

Tags :

Share :

Latest Posts

Categories

Tags

Follow Peter’s China IP Briefings

Follow Peter Lin on LinkedIn

Subscribe to the China IP Gateway Newsletter

Watch 60-Second China IP Shorts

Related Posts

12 vs. 30 Months: Mastering the Critical Windows for China Patent Protection

We Filed in China — Can We Still Protect the Invention in Hong Kong? A Practical Guide for PCT and China Patent Applicants

China Patent vs Hong Kong Patent: What Is the Difference?

Before You Manufacture in China: How Trademark, Patent, and Contract Protection Work Together

From Idea to Income: Navigating the Chinese PCT National Phase with the Slimming Strategy

Missed the Hong Kong Re-Registration Window: Can Standard Patent (O) Still Help?

PCT Translation Errors in China: What Foreign Applicants Can Correct, and When

Provisional vs. Non-Provisional Patent Applications — Which One Fits Your Kickstarter Launch?

What a China Manufacturing Agreement Should Say About Tooling and Molds

Adult Products Often Get Rejected for Patents in China—Why?

China Takes Half of the World's Patent Filings — What the Data Really Means for Global Innovation

How Much Can You Really Amend Claims When Entering China via PCT?

How to Protect Your Idea Quickly in China: A Personal Note from the Train

PCT Entry into China: Lessons from my 45-day Journey with Sarah, a British Inventor

Paris Convention vs. PCT in China: A Critical Difference Most Inventors Miss

PCT Patent Entry into China: A Cost Lock-In Mechanism Many Applicants Overlook

A Simple Way to Cut China Patent Costs When Using PCT — Without Giving Up Protection

If a Translation Error Narrows Your Patent in China — Will CNIPA Be Sympathetic?

Two Inventors. Two Views on China Patents. One Hard Reality.

services

Contact Info